Clinical Trials

This study is testing whether a medicine called metformin can help treat aortic aneurisms in the abdomen. The study will use imaging tests to examine whether metformin can help prevent these aortic aneurisms from getting bigger. To participate in this study, you must be 55 to 90 years old and diagnosed with an abdominal aortic aneurism. This study takes place in Stanford, California.

Are you scheduled for open-heart surgery for your aortic valve? This study aims to look at changes in inflammation and gene activity while surgery patients are on a heart-lung bypass machine. To participate in this study, you must be at least 20 years old and be scheduled for aortic valve surgery, either with or without coronary artery bypass grafting (CABG). This study is located in Boston, Massachusetts.

Did you develop atrial fibrillation after coronary artery bypass graft (CABG) surgery? Did you develop atrial fibrillation after a coronary artery bypass grafting (CABG) surgery? This study is looking at how well oral anticoagulation medicines work to prevent complications, such as blood clots and heart attack, for patients who experience post-operative atrial fibrillation (POAF). This study is in multiple locations around the country.

The study is to investigate that the worsening orthostatic tachycardia and symptoms after glucose ingestion in POTS patients are due to a greater increase in splanchnic venous capacitance and excessive blood pooling during an orthostatic challenge.

Are you in need of a heart or lung transplant or have you had one in the past 3 months? Have you undergone a lung or heart transplant in the past 3 months or are you a candidate for heart or lung transplant? Some people with advanced heart and lung disease have heart and lung transplants but these new organs are often rejected. When this happens, patients must have repeated biopsies, which are invasive and expensive. Researchers in this clinical study want to see if a blood test can predict organ rejection and take the place of biopsies. To participate, you must be 18 to 80 years old and be a candidate for heart or lung transplant or have had a heart or lung transplant no more than three months ago. The study is taking place in Bethesda, Maryland, at the NIH Clinical Center, as well as in Baltimore, Maryland, and Falls Church, Virginia.

The purpose of this study is to see if adding a drug called Regadenoson to the EVLP circulation reservoir during perfusion of marginal donor lungs will help increase the likelihood that the donor lungs will become usable for transplantation.

The purpose of this study is to evaluate whether biomarkers of lung injury and remodeling are responsive to effective continuous positive airway pressure (CPAP) treatment in adults with idiopathic pulmonary fibrosis (IPF) and moderate-to-severe obstructive sleep apnea (OSA).

Do you have short telomeres and a telomere gene mutation? Some people who have aplastic anemia have very short telomeres, which protect the ends of DNA in chromosomes. This study is testing whether low doses of the medicine danazol help prevent telomeres from getting shorter and reduce signs of damage from aplastic anemia or related conditions. Participants in this study must be 3 years or older and have a telomere disease and signs of aplastic anemia, lung disease such as pulmonary fibrosis, or liver disease. This study is located in Bethesda, Maryland.

Are you an adult who has idiopathic pulmonary fibrosis or an advanced lung cancer? This study aims to see whether a new imaging dye for positron emission tomography (PET) is effective at looking at fibrosis in lung cancer and idiopathic pulmonary fibrosis (IPF). Participants will be given the imaging dye and then receive a PET scan. To participate in this study, you must either be between 18 and 80 years old and have lung cancer or be a healthy volunteer or be between 50 and 80 years old and have IPF. This study is located in Boston, Massachusetts.

Are you between 40 and 85 with worsening idiopathic pulmonary fibrosis? This study aims to test a new combination treatment for acute exacerbations, a life-threatening complication of idiopathic pulmonary fibrosis (IPF) that has no approved treatment. The treatment is meant to help stop part of the immune system from further injuring the lung tissue. To participate in this study, you must be between 40 and 85 years old and have worsening IPF. This study is located in Birmingham, Alabama; Boston, Massachusetts; Philadelphia, Pennsylvania; and Pittsburgh, Pennsylvania.